Lung Cancer Clinical Trial
Phase I Combination Ixabepilone + Cisplatin
Summary
The purpose of this study is to determine the highest dose of ixabepilone that can be given safely with cisplatin without causing severe or life-threatening side effects and for some patients with non-small cell lung cancer, the effects (good or bad) on your cancer will also be studied
Eligibility Criteria
Escalation Phase Subjects: Primary solid tumor not curable by local measures such as surgery, radiation
Inclusion Criteria:
Men and women age ≥ 18
Exclusion:
More than 2 prior chemotherapy containing regimens for metastatic disease
No prior exposure to cisplatin or ixabepilone
Expansion Phase Subjects: Advanced Non-small cell lung cancer
Inclusion Criteria:
Men and women age ≥ 18
Exclusion:
No prior chemotherapy-containing regimen for metastatic disease
No prior exposure to cisplatin or ixabepilone
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 7 Locations for this study
Washington District of Columbia, 20007, United States
New Brunswick New Jersey, 08901, United States
Hershey Pennsylvania, 17033, United States
Lucca , 55100, Italy
Meldola (Fc) , 47014, Italy
Rimini , 47900, Italy
Viterbo , 01100, Italy
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.